20/20 Biolabs is presenting its OneTest MCED test, which utilizes biomarker tracking, machine learning, and an anti-inflammatory diet score. A new law passed in February 2026 establishes a statutory pathway for Medicare coverage of MCED blood tests starting in 2028, contingent on FDA authorization and CMS clinical appropriateness. The company believes OneTest is well-positioned for this pathway, subject to regulatory approvals. The presentation contrasts OneTest with ctDNA-based tests, citing Grail's NHS-Galleri trial results which showed a missed primary endpoint and limitations in early tumor detection and serial testing practicality. OneTest's approach involves serial testing (every 3-4 months) to track biomarker trajectories and velocity, aiming for higher sensitivity and specificity. The test also incorporates a Dietary Inflammatory Index (DII) to assess and guide diet changes. Evidence supporting FDA authorization and CMS coverage includes data from CGMH Taiwan, BIOINFRA Korea, MD Anderson MCAST, SeekIn, NCI PLCO, and a U.S. firefighter cohort. OneTest is currently offered as a Laboratory Developed Test (LDT) and has not yet received FDA authorization. The company's M&A strategy focuses on acquiring vertically or horizontally integrated companies in health and wellness. Revenue projections are presented, assuming FDA approval and CMS reimbursement, with a comparison to Exact Sciences' Cologuard revenue growth post-Medicare coverage.